Survival and predictors of mortality among HIV-infected adults after initiation of antiretroviral therapy in Eastern Ethiopia Governmental hospitals, from January 2015 to December 2021 (multi-center retrospective follow-up study) Authors: Girum Shibeshi Argaw, Kasahun Alemu Gelaye, Ayenew Molla Lakew, Fnatu Mamo Aragaw, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Negalign Byadge Gelaw Published: 2024 ABSTRACT BackgroundHuman Immune Deficiency Virus (HIV) remains the leading cause of morbidity and mortality globally. It can lead to Acquired Immunodeficiency Syndrome (AIDS), which results in gradual deterioration and failure of the immune system. As the immune system becomes compromised, the patient becomes highly susceptible to life-threatening infection which ends with early death. Even though Antiretroviral Therapy (ART) significantly decreases mortality as a whole, the rate of death is still the highest, especially in the first and second years of ART initiation. The study aims to assess the survival and predictors of mortality among HIV-infected adults after initiation of antiretroviral therapy in Jigjiga City Governmental Hospitals, Eastern Ethiopia.MethodInstitution-based Retrospective follow-up study was employed among ART patients from January 1, 2015, to December 31, 2021. Data were cleaned and entered in Epi-data version 3.1 and exported to STATA 14 for further analysis. Kaplan–Meier and Log-Rank tests were applied to compare survival differences among categories of different variables. In bi-variable analysis, P-values < 0.20 were included in a multivariable analysis. A multivariable Cox regression model was used to measure the risk of death identify the and significant predictors of death. Variables that a P-value < 0.05 were considered statistically significant predictors of mortality.ResultIn this study 466(53.34%) participants were male and 552(65.56%) were urban residents about 91(10.81%) have died with an overall incidence rate of 3.92 (95% CI (2.43–5.41)) per 100-person year of observation. The overall survival probability of the study group was 83.97%. In the multivariable Cox regression analysis, baseline World Health Organization (WHO) stage III/IV (AHR = 2.42(1.43–4.09)) have no caregiver (AHR = 2.23; 95% CI (1.16–4.29)), being bedridden functional status (AHR = 2.18; 95% CI (1.01–4.72)), and poor last known adherence level (AHR = 4.23; 95%CI (2.39–7.47)) were found to be significant predictors of mortality.ConclusionThe incidence of death was relatively high, especially in the second year of ART. Baseline clinical WHO stage III/IV, bedridden functional status at enrolment, and absence of caregiver, poor level of recent adherence were found to be independent predictors of mortality. Patients with these risk factors need special attention and are crucial to reducing the rate of mortality. Background Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) related morbidity and mortality remain a global public health concern, especially in the African region, which is still a highly troubled region with the pandemic [1, 2]. Based on Global HIV/AIDS statistics of 2022 fact sheets, on average, around 40.1 million people died from AIDS-related illnesses worldwide, since the start of the epidemic and 650,000 individuals died in 2021 [3]. Nowadays antiretroviral treatment for People Living With HIV (PLWH) is widely available. However, PLWHs especially in the African region including Ethiopia, still hesitate to start the treatment early and are less committed to persisting with the treatment, which leads to the rapid progression of the disease to the advanced stage and turn to HIV-related early mortality [4–6]. At the end of 2021, 28.7 million people accessed antiretroviral therapy and it has a significant role in improving the survival status among PLWH [7, 8]. The substantial reduction in AIDS-related deaths is accredited to the global scale-up of ART services. By the end of 2021, 75% of PLWH knew their serostatus, 76% of those who knew their HIV status received ART, and 80% of those on treatment suppressed their viral load [3, 9]. Even though none of the countries achieved the 90–90–90 UNAIDS targets, which means by 2020 (90% of all people living with HIV will know their HIV status, 90% of all people diagnosed with HIV infection will receive sustained ART, 90% of all people receiving ART will have viral suppression). The lowest achievement rates also were in low and middle-income countries, which indicate less likely to achieve the target easily, and HIV-related mortality kept the global burden. Test and treat is an intervention strategy in which the population at risk is screened for HIV infection and diagnosed PLWH receive treatment as soon as early after being confirmed, aiming to eliminate HIV and reduce the rate of spreading the virus to other people [3, 10]. It assists in profoundly screening HIV-infected individuals in the population and promoting their early treatment to keep them immune-competent, not only for their suppression from the progression of HIV infection but also for the public benefit of protecting others being infected [8, 10]– [12, 42]. Ethiopia launched the universal test and treat strategy in 2015 throughout the nation; it had remarkable improvement in the treatment outcome. Following this strategy, Ethiopia has one of the lowest HIV prevalence rates in East Africa, but there are still more than one million people estimated to be living with HIV in Ethiopia [13, 14]. Based on the Ethiopia Public Health Institute (EPHI) HIV estimation and projection report in 2020, 5002 individuals died in 2020 and 4843 died in 2021. In the study area (Ethio-Somali region), there were 130 and 111 death reports in 2020 and 2021 respectively [15]. The proportions of AIDS-related mortality vary between African countries ranging from 4.5–29.7% [16–22]. At 11.8%, Ethiopia is also among the high burden of HIV/AIDS-related mortality [18, 19, 21]– [24]. According to the prior studies, the overall incidence rate for mortality has ranged from 1.89 per 100-person-year observation to 13.56 per 100-person-year observation [18, 25] – [31]. The previous studies reported important predictors of mortality like socio-demographic, treatment, and clinical related factors that sex [24, 32, 33], age [27, 28, 31, 35, 36], place of residence [4], anemia status [19, 24, 25, 27, 31, 36], disclosure status [23], functional status [4, 18, 19, 22, 31, 38] adherence level [18, 19, 23, 26, 27] World health organization(WHO) clinical stage [18, 24, 29, 36, 37], baseline opportunistic infection [20, 29, 33, 41], Tuberculosis co-infection [26, 39, 42], CD4 count at baseline [22, 35, 37, 39, 40], cotrimoxazole prophylaxis [4, 23], Isoniazid (INH) Preventive Therapy [20, 21] were directly associated with mortality in adult HIV/AIDS patients on ART. There were many studies conducted in the country. However, there was no newly updated information about the above factors, which contribute to the mortality of adult PLWH after ART initiation, in the study area. Moreover, some important variables such as hemoglobin level, disclosure status, recent adherence level, and caregiver status are not addressed by most of the previous studies. In addition to the added variables majority of studies were concerned with incidence and predictors, rather we incorporated both concepts and tried attention to the median survival time of the patients as well. Consequently, this study aimed to assess the survival and predictors of mortality among adults with PLWH after initiation of antiretroviral therapy at Jigjiga City governmental Hospitals, in Eastern Ethiopia. The findings of this study might provide researchers for program planners, decision-makers, ART program implementers, and healthcare providers at different levels by enabling them to access predictors of mortality after the advancement of ART. Methods Study design and setting A multi-center institution-based retrospective follow-up study was employed in Jigjiga City Governmental Hospitals, in eastern Ethiopia by including the ART data from January 01/2015 to December 31/2021. Jigjiga is the capital city of the Somali region, Ethiopia, which is located 631 km from Addis Ababa, the capital city of Ethiopia. The study was conducted in three governmental hospitals in the city, which all have an ART clinic in their routine patient care service. All three Hospitals (Karamara Hospital, Sheik Hassen Yeberre referral Hospital, and Ablele Primary Hospital) ART clinics provided HIV/AIDS interventions, including free diagnosis, treatment, and patient follow-up. The study was conducted from July 1 to 30 July 2022. Population All adults aged 15 years and above whom newly started ART at Jigjiga City Governmental Hospitals from Jan 1, 2015, to December 31, 2021, and, Patients who had at least one-month follow-up visit after ART initiation were included in this study. Whereas PLWH who transferred in with incomplete baseline data (information), and those patients who had unknown ART initiation dates were excluded from this study. The research question was developed and data was analyzed from previously published papers with the same author [43]. Sample size determination and sampling procedure The study applied a purposive sampling technique to include the two largest hospitals and one primary hospital; those were the only ART clinic centers in the city. The sample size for the predictors was estimated by using the survival analysis formula power Cox Command with STATA 14 software. The calculation was done based on the assumption that type I error of 5%, power of 80%,15% expected incomplete records, and the exposure is Cotrimoxazole Preventive Therapy(CPT) Prophylaxis the most significant variable which gives the maximum sample size with the probability of patients did not take CPT prophylaxis = 1.48 [4]. The patient’s chart number was taken from the electronic database of the three Hospitals. There were about 2016 PLWH who enrolled in ART within the seven years, and 1816 fulfilled the inclusion criteria. Since we have a budget constraint and are unable to take all records. We applied stratified proportionate random sampling among hospitals and we applied a simple random sampling technique (computer-generated RS) by using SPSS Software for selecting the minimum total sample size. Then, 842 charts were selected as a final sample size. Data collection tools & procedures ART data is stored both in the form of hard copy (chart) and in database form in smart care. Data about mortality had been collected from patient charts by using a checklist or a data extraction sheet. The data extraction sheet was designed based on study objectives. In preparing the tool, forms used for laboratory request records and ART intake forms were considered and included. Before data collection, training was given to data collectors regarding the tool and the way they collect the data from the chart as well. About seven clinical nurses and health officers as data collectors and three supervisors were recruited. Patient charts were selected from the chart room by using the Medical Registration Number (MRN) which was taken from the smart care and then data were extracted from the patient’s medical charts by using the prepared tool. A unique code was given for each selected chart after data was extracted so that there might be no chance of redundant collection of data from the same chart. Operational definition In this study, the main outcome variable is Mortality related to AIDS other than deaths due to accidents like car accidents, bullet injuries, and any suicidal related. Censored; lost to follow-up, transferred out and those actively on ART care until the end of the study were considered as censored. Functional status of patients; Classified according to the World Health Organization (WHO) criteria as working (W): capable of going out of home and doing routine activities including the daily work; Ambulatory (A): capable of self-care and going to the toilet unsupported; Bed-ridden (B): not able to perform an activity of daily living [22]. Anemia; is defined as anemic or not anemic based on WHO criteria: i.e. Hemoglobin (Hgb) concentration < 12 g/dl for females and < 13 g/dl for males [44]. Adherence level to ART drug; is classified as, Good (greater or equal to 95%adherence or missing 1 out of 30 doses or missing 2 out of 60 doses), Fair (85–94% adherence or missing 2–4 out of 30 doses or missing 4–9 out of 60 doses), Poor (less than 85% or missing 5 doses of 30 doses or 10 doses out of 60 doses as well) [45]. Data quality control & assurance The quality also checks with different individuals during the initial recording and the entire data collection process as well. Both supervisors and principal investigator were closely following the data collection process. We proved consistency between data recording systems and the prepared checklist by randomly selecting and completing 5% sample chart reviews before two weeks of actual data collection, which resulted in slight modifications to the data extraction tool. All checklists collected per day were reviewed and checked for any errors, completeness, clarity, and missing values and appropriate corrections were taken accordingly. Data processing and analysis After the data were extracted from the chart, it was checked for consistency and completeness before the data entry. The data was entered in Epi-data 3.1 and exported to STATA 14 for further analysis. Descriptive statistics like; proportions, median, Standard deviation(SD), Inter-Quartile Range(IQR), tables, and charts were done to describe the characteristics of study participants. To handle missing data, we used multiple imputations, and the percentage of missing data was below 5% and it was minimal. Nonparametric estimations of Kaplan–Meier were done graphically and the Log-rank test was used to compare the survival probabilities of each categorical variable. After fitting the survival model, the proportional hazard assumption has been checked by using a Schoenfeld graphical and global test (goodness test) as well as the time variate covariate (tvc) method for the time-dependent variable. Multiple imputations were done to manage missing data, and there were few missing data (< 5%). The model adequacy was checked by The Schoenfeld residuals and The Cox-Snell residuals (together with their Nelson-Aalen cumulative hazard function). Variables with a P-value of < 0.20 in the bi-variable analysis were eligible for multivariable Cox Regression analysis. Both crude and adjusted hazard ratio with their 95% Confidence interval was computed to show the strength of the association. Finally, from multi-variable analysis, those variables with a P-value < 0.05 were considered statistically significant. Result Baseline Socio-demographic, clinical, and treatment-related characteristics Among 842 patients, 466(53.34%) of the study participants were males and the majority 65.56% (n = 552) were urban residents, with 473(56.18%) residing within 5 km of the health facility. The median age of the participants was 35(IQR = ± 14) years (Table 1). Among Clinical and treatment-related predictors, about 240(42.93%) patients were linked to care with a baseline CD4 count between 201 and 350 cells/ml. The majority of 369(43.82%) of the participants were WHO stage II, and around 89.96% have been started with Cotrimoxazole prophylaxis therapy. The majority (96.32%) of patients were screened for Tuberculosis(TB), of which 18.67% were TB-positive (Table 2). Comparison of the Survival Probability (Log Rank Test & Kaplan–Meier Survival curve) The Log-rank test was applied to check if there was any significant difference in survival status among the various levels of categorical variables. Based on the Log-rank test, there was a significant difference between Cotrimoxazole preventive therapy(p = 0.0001)age category (P = 0.03), Baseline Hemoglobin level (p = 0.0081), residence(p < 0.001), functional status (p < 0.001)baseline and recent adherence level (p < 0.001), baseline WHO stage (P < 0.001), last known WHO stage (P < 0.001), disclosure status(p < 0.001), occupational status (p < 0.001), baseline CD4 count (p < 0.001), distance from a health facility (p < 0.001), caregiver < 0.001), baseline BMI (P < 0.001), baseline functional status (p < 0.001), last known adherence (p < 0.001), and TB treatment history (p = 0.002). Fig. 1Non-parametric estimates of cumulative survival curves across categories of Baseline CD4 count (A) and cotrimoxazole prophylaxis therapy (B), in Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 Non-parametric estimates of cumulative survival curves across categories of Baseline CD4 count (A) and cotrimoxazole prophylaxis therapy (B), in Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 Based on the Kaplan–Meier survivor estimate being rural residence, comorbidity, baseline CD4 count below 200 cells, those not taken CPT Prophylaxis(Fig. 1), poor baseline and last known adherence level, non-disclosed HIV status have lower survival status or were at higher risk of death as compared with their counterparts (Fig. 2). Fig. 2Non-parametric estimates of cumulative survival curves across categories of Disclosure Status (C), and recent adherence level (D), in Jigjiga City Governmental Hospitals from January 1, 2015, to December 31, 2021 Non-parametric estimates of cumulative survival curves across categories of Disclosure Status (C), and recent adherence level (D), in Jigjiga City Governmental Hospitals from January 1, 2015, to December 31, 2021 The Kaplan–Meier survival estimation showed that the overall estimated survival rate after the initiation of antiretroviral therapy (ART) was 83.97% (95% CI = 80.05–87.19%) at 85 months of follow-up (Fig. 3). Fig. 3Overall Kaplan–Meier Survival estimates of patients starting ART in Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 Overall Kaplan–Meier Survival estimates of patients starting ART in Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 The survival probability of the cohort at 3 months, 6 months, 1, 2, 3, 4, 5, 6, and 7 years was 98.56%, 97.94%, 94.99%, 89.74%, 87.37%, 86.13%, 85.83%, 84.91%, 83.97%respectively (Table 3). The overall failure probability of the cohort was 16.03% at 85 months of follow up periods. Table 1Baseline socio-demographic characteristics for adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021VariablesFrequency(N)Percentage (%) sex Female Male46637655.3444.66 Age 15–24 25–34 35–44 ≥459026529818910.6931.4735.3922.45 Marital status Single Married Divorced Others*12142819010314.3750.8322.5712.23 Educational status No education Primary Secondary College& university21427024511325.4232.0729.1013.42 Residence Urban Rural55229065.5634.44 Distance from health facility Below 10 km 10 km & above36940743.8256.18 Occupation Unemployed Daily laborers Housewife Gov’t employee Others**19610112618923023.2812.0014.9622.4527.31 Caregiver Yes No7598290.259.75 Disclosure status Disclosed Not disclosed67316880.0219.98"Others*=widowed, separatedOthers**=self-employee, teacher, soldiers, students, farmers Table 1Baseline socio-demographic characteristics for adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021VariablesFrequency(N)Percentage (%) sex Female Male46637655.3444.66 Age 15–24 25–34 35–44 ≥459026529818910.6931.4735.3922.45 Marital status Single Married Divorced Others*12142819010314.3750.8322.5712.23 Educational status No education Primary Secondary College& university21427024511325.4232.0729.1013.42 Residence Urban Rural55229065.5634.44 Distance from health facility Below 10 km 10 km & above36940743.8256.18 Occupation Unemployed Daily laborers Housewife Gov’t employee Others**19610112618923023.2812.0014.9622.4527.31 Caregiver Yes No7598290.259.75 Disclosure status Disclosed Not disclosed67316880.0219.98"Others*=widowed, separatedOthers**=self-employee, teacher, soldiers, students, farmers Baseline socio-demographic characteristics for adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021 sex Female Male 466 376 55.34 44.66 Age 15–24 25–34 35–44 ≥45 90 265 298 189 10.69 31.47 35.39 22.45 Marital status Single Married Divorced Others* 121 428 190 103 14.37 50.83 22.57 12.23 Educational status No education Primary Secondary College& university 214 270 245 113 25.42 32.07 29.10 13.42 Residence Urban Rural 552 290 65.56 34.44 Distance from health facility Below 10 km 10 km & above 369 407 43.82 56.18 Occupation Unemployed Daily laborers Housewife Gov’t employee Others** 196 101 126 189 230 23.28 12.00 14.96 22.45 27.31 Caregiver Yes No 759 82 90.25 9.75 Disclosure status Disclosed Not disclosed 673 168 80.02 19.98 "Others*=widowed, separated Others**=self-employee, teacher, soldiers, students, farmers Incidence of mortality patients on ART The study subjects followed a total of 85.06 months after initiation of treatment and followed for the different periods with a median time of 28.7 months (IQR: 13.9-50.43) with a total observation time of 2324.3 person-years. Out of 842 patients enrolled, 91(10.81%) were dead, 122(14.49%) had been Lost To Follow-Up (LTFU), 114(13.54%) were transferred out and 515(61.16%) were still on treatment until the end of the study. During the total follow-up periods, the overall incidence rate of mortality was 3.92 (95% CI(2.43–5.40)) per 100-person year of observation. Over the 85.06 month follow-up period; 5.42 per 100 adult-months (95% CI (3.97–7.32)) died during the first 12 months of follow-up, followed by 5.55 (95% CI (3.86–7.80))/100-person year died during the second year of follow-up. Table 2Clinical and treatment-related characteristics of adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021VariablesFrequencyPercentage (%)Baseline WHO stage Stage I/II Stage III or IV59824471.0228.98The last known WHO stage Stage I/II Stage III or IV65918378.2721.73Baseline CD4 count Below 200 cell 201–350 cell Above 350 cell27525529233.4531.0235.52OI at enrollmentYesNo24457729.7270.28Functional status(baseline) working Ambulatory Bed-ridden5292833062.8333.613.56BMI Below 18.5 kg/m2 18.5–24.9 kg/m2 ≥25 kg/m220651012624.4760.5714.96CPT prophylaxis Yes No5766589.8610.14INH prophylaxis Yes No4879284.1115.89TB screening status at baseline Positive Negative14466718.6781.33Current TB status/last known/ Positive Negative9974311.7688.24Baseline Hemogulobin level Severe anemia Moderte anemia Mild anemia No anemia562651983196.6831.6223.6338.07TB Treament History Yes No577856.7793.23Baseline adherence Good Fair poor48520715057.6024.5817.81last known adherence Good Fair poor5412109064.3324.9710.70 Table 2Clinical and treatment-related characteristics of adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021VariablesFrequencyPercentage (%)Baseline WHO stage Stage I/II Stage III or IV59824471.0228.98The last known WHO stage Stage I/II Stage III or IV65918378.2721.73Baseline CD4 count Below 200 cell 201–350 cell Above 350 cell27525529233.4531.0235.52OI at enrollmentYesNo24457729.7270.28Functional status(baseline) working Ambulatory Bed-ridden5292833062.8333.613.56BMI Below 18.5 kg/m2 18.5–24.9 kg/m2 ≥25 kg/m220651012624.4760.5714.96CPT prophylaxis Yes No5766589.8610.14INH prophylaxis Yes No4879284.1115.89TB screening status at baseline Positive Negative14466718.6781.33Current TB status/last known/ Positive Negative9974311.7688.24Baseline Hemogulobin level Severe anemia Moderte anemia Mild anemia No anemia562651983196.6831.6223.6338.07TB Treament History Yes No577856.7793.23Baseline adherence Good Fair poor48520715057.6024.5817.81last known adherence Good Fair poor5412109064.3324.9710.70 Clinical and treatment-related characteristics of adult HIV patients on ART in Jigjiga City Governmental hospitals from January 1, 2015, to December 31, 2021 Baseline WHO stage Stage I/II Stage III or IV 598 244 71.02 28.98 The last known WHO stage Stage I/II Stage III or IV 659 183 78.27 21.73 Baseline CD4 count Below 200 cell 201–350 cell Above 350 cell 275 255 292 33.45 31.02 35.52 OI at enrollment Yes No 244 577 29.72 70.28 Functional status(baseline) working Ambulatory Bed-ridden 529 283 30 62.83 33.61 3.56 BMI Below 18.5 kg/m2 18.5–24.9 kg/m2 ≥25 kg/m2 206 510 126 24.47 60.57 14.96 CPT prophylaxis Yes No 576 65 89.86 10.14 INH prophylaxis Yes No 487 92 84.11 15.89 TB screening status at baseline Positive Negative 144 667 18.67 81.33 Current TB status/last known/ Positive Negative 99 743 11.76 88.24 Baseline Hemogulobin level Severe anemia Moderte anemia Mild anemia No anemia 56 265 198 319 6.68 31.62 23.63 38.07 TB Treament History Yes No 57 785 6.77 93.23 Baseline adherence Good Fair poor 485 207 150 57.60 24.58 17.81 last known adherence Good Fair poor 541 210 90 64.33 24.97 10.70 Assessing Proportional Hazard Assumption and Model Fitness Proportional hazard assumption can be checked by three techniques, the Schoenfeld residual global test, and comparing the estimated ln(-ln) survivor curves versus ln (survival time) over different categories of variables (Fig. 4). Based on Schoenfeld residual global test result (Chi square = 13.12, with p-value = 0.7283) indicates that the Proportional Hazard (PH) assumption is satisfied. The Cox-Snell residuals (together with their Nelson Aalen cumulative hazard function) have been tested to check the goodness of fit. Fig. 4Plot for assessing the proportional hazard of Caregiver status, TB co-infection, and Baseline Adherence level of Patients at Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 Plot for assessing the proportional hazard of Caregiver status, TB co-infection, and Baseline Adherence level of Patients at Jigjiga City Governmental Hospitals from January 1, 2015 to December 31, 2021 For the overall model, the figure shows that the plot of the Nelson Aalen cumulative hazard function with Cox-Snell follows the 45° line closely overlays the Nelson–Aalen cumulative hazard, showing us the model is well fit. Table 3Life table showing pattern (survival status) of death with Time intervals among PLWH on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021Time interval in monthsFailure/DeathSurvival probability95% CI[0 to 3] months120.98560.9748, 0.9918(3 to 6] months50.97940.9671, 0.9872(6 to 12] months220.94990.9320,0.9632(12 to 24] months320.89740.8722, 0.9179(24 to 36] months110.87370.8450, 0.8975(36 to 48] months40.86130.8300, 0.8873(48 to 60] months30.85830.8135, 0.8771(60 to 72] months10.84910.8005, 0.8719(72 to 84] months10.83970.8005, 0.8719 Table 3Life table showing pattern (survival status) of death with Time intervals among PLWH on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021Time interval in monthsFailure/DeathSurvival probability95% CI[0 to 3] months120.98560.9748, 0.9918(3 to 6] months50.97940.9671, 0.9872(6 to 12] months220.94990.9320,0.9632(12 to 24] months320.89740.8722, 0.9179(24 to 36] months110.87370.8450, 0.8975(36 to 48] months40.86130.8300, 0.8873(48 to 60] months30.85830.8135, 0.8771(60 to 72] months10.84910.8005, 0.8719(72 to 84] months10.83970.8005, 0.8719 Life table showing pattern (survival status) of death with Time intervals among PLWH on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021 Predictors of Mortality From the bi-variable Cox Proportional Hazard regression, residence, marital status, distance from the health facility, caregiver, disclosure status, baseline WHO clinical stage, functional status, and recent adherence level were associated with survival status at P < 0.20. Those significant variables in bi-variable analysis were included in multivariable analysis and baseline WHO stage, recent adherence level, and caregiver were found to be statistically significant predictors of mortality at 5% level of significance. Based on multivariate analysis, keeping the effect of other variables constant, the hazard of death among patients who ‘have no caregiver was 2.23(AHR = 2.23; 95% CI (1.16–4.29) p-value = 0.031)’ times higher as compared with their counterparts. Respondents with a poor level of adherence had 4.23(AHR = 4.23; 95%CI (2.39–7.47) p-value = 0.024) times the higher hazard of mortality as compared to those who were on a good level of adherence. Those who were on bedridden functional status had a 2.18 times higher chance of death compared to those who were on working functional status (AHR = 2.18; 95% CI (1.01–4.72) p-value = 0.0001). Moreover, the hazard of mortality in patients with their baseline ‘WHO stage III/IV was 2.42(AHR = 2.42(1.43–4.09) p-value = 0.006)’ times higher as compared with respondents with their baseline WHO stage I/II (Table 4). Table 4Bi-variable and multivariable Cox Regression Model for assessing predictors of mortality among adult HIV-Positive patients on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021VariablesHazard ratio with 95% Confidence intervalCHR (95% CI)AHR (95% CI)Residence Rural Urban1.002.012(1.332–3.038)1.001.106(0.703–1.741)Age(years) 15–24 25–34 35–44 ≥450.692(0.277–1.734)0.824(0.439–1.544)1.977(1.024–3.691)1.000.662(0.238–1.839)0.911(0.469–1.765)1.301(0.752–2.283)1.00Marital status Single Married Divorced Others1.208(0.647–2.255)1.001.205(0.712–2.039)1.629(0.914-903)1.012(0.481–2.127)1.000.930(0.533–1.623)0.739(0.387–1.416)Distance from health facility Below 10 km 10 km & above1.002.485(1.525–4.049)1.001.795(0.759–2.499)Caregiver Yes No1.004.188(2.605–6.733)1.002.229(1.158–4.288) *Disclosure status Disclosed Non-disclosed1.002.374(1.525–3.696)1.000.908(0.498–1.657)Functional status Working Ambulatory Bedridden1.002.442095(1.547–3.856)3.936(1.921–6.230)1.001.292(0.746–2.238)2.179(1.006–4.719) **Recent adherence level Good Fair Poor1.001.514(0.146–2.754)4.023(1.155–7.873)1.002.704(1.620–4.513) *4.232(2.399–7.465) *Baseline WHO Stage Stage I/II Stage III/IV1.004.198(2.764–6.375)1.002.421(1.429–4.099) **= P ≤ 0.05; **= P ≤ 0.01 Table 4Bi-variable and multivariable Cox Regression Model for assessing predictors of mortality among adult HIV-Positive patients on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021VariablesHazard ratio with 95% Confidence intervalCHR (95% CI)AHR (95% CI)Residence Rural Urban1.002.012(1.332–3.038)1.001.106(0.703–1.741)Age(years) 15–24 25–34 35–44 ≥450.692(0.277–1.734)0.824(0.439–1.544)1.977(1.024–3.691)1.000.662(0.238–1.839)0.911(0.469–1.765)1.301(0.752–2.283)1.00Marital status Single Married Divorced Others1.208(0.647–2.255)1.001.205(0.712–2.039)1.629(0.914-903)1.012(0.481–2.127)1.000.930(0.533–1.623)0.739(0.387–1.416)Distance from health facility Below 10 km 10 km & above1.002.485(1.525–4.049)1.001.795(0.759–2.499)Caregiver Yes No1.004.188(2.605–6.733)1.002.229(1.158–4.288) *Disclosure status Disclosed Non-disclosed1.002.374(1.525–3.696)1.000.908(0.498–1.657)Functional status Working Ambulatory Bedridden1.002.442095(1.547–3.856)3.936(1.921–6.230)1.001.292(0.746–2.238)2.179(1.006–4.719) **Recent adherence level Good Fair Poor1.001.514(0.146–2.754)4.023(1.155–7.873)1.002.704(1.620–4.513) *4.232(2.399–7.465) *Baseline WHO Stage Stage I/II Stage III/IV1.004.198(2.764–6.375)1.002.421(1.429–4.099) **= P ≤ 0.05; **= P ≤ 0.01 Bi-variable and multivariable Cox Regression Model for assessing predictors of mortality among adult HIV-Positive patients on ART in Jigjiga City Governmental hospitals from January 1, 2015 to December 31, 2021 Residence Rural Urban 1.00 2.012(1.332–3.038) 1.00 1.106(0.703–1.741) Age(years) 15–24 25–34 35–44 ≥45 0.692(0.277–1.734) 0.824(0.439–1.544) 1.977(1.024–3.691) 1.00 0.662(0.238–1.839) 0.911(0.469–1.765) 1.301(0.752–2.283) 1.00 Marital status Single Married Divorced Others 1.208(0.647–2.255) 1.00 1.205(0.712–2.039) 1.629(0.914-903) 1.012(0.481–2.127) 1.00 0.930(0.533–1.623) 0.739(0.387–1.416) Distance from health facility Below 10 km 10 km & above 1.00 2.485(1.525–4.049) 1.00 1.795(0.759–2.499) Caregiver Yes No 1.00 4.188(2.605–6.733) 1.00 2.229(1.158–4.288) * Disclosure status Disclosed Non-disclosed 1.00 2.374(1.525–3.696) 1.00 0.908(0.498–1.657) Functional status Working Ambulatory Bedridden 1.00 2.442095(1.547–3.856) 3.936(1.921–6.230) 1.00 1.292(0.746–2.238) 2.179(1.006–4.719) ** Recent adherence level Good Fair Poor 1.00 1.514(0.146–2.754) 4.023(1.155–7.873) 1.00 2.704(1.620–4.513) * 4.232(2.399–7.465) * Baseline WHO Stage Stage I/II Stage III/IV 1.00 4.198(2.764–6.375) 1.00 2.421(1.429–4.099) * *= P ≤ 0.05; **= P ≤ 0.01 Discussion This retrospective cohort study analyzed seven years of record data of PLWH on ART from three ART clinic centers in Jigjijga city. The study assessed the incidence and predictors of mortality among adult HIV patients on ART at Jigjiga City Governmental Hospitals, Eastern Ethiopia. Nearly 11% of those enrolled in ART had died within seven years. The overall survival probability of the study population was 83.97%, and the overall incidence rate of mortality among PLWH who are on ART was 3.92 (95% CI (3.20–4.81)) per 100-person year of observation. These findings are consistent with other studies conducted in different parts of Ethiopia [20, 21, 24, 33]. This similarity in Ethiopian studies may be due to the implementation of similar treatment and care protocols designed by WHO as a treatment guideline made provision of consistent service or care practice throughout the country and the population characteristics also almost similar across the region. The findings from the current study have been higher than other studies conducted in Indian public hospitals [29], Nekemte Ethiopia [28]. But some studies reported higher finding of incidence rates compared with the current findings [4, 23, 25, 26, 31, 32]. This discrepancy in results and the variation in mortality rates between these studies may be due to differences in the clinical characteristics of study participants and differences in study periods (length of follow-up), sample sizes, and study settings, as our study included multi-center involvement and we included the patients those who started ART after test and treat strategy. This study identified caregiver status, baseline WHO clinical stage, current/last known adherence level, and baseline functional status as important predictors of mortality among HIV patients who are on ART follow-up in the study area. This finding revealed that patients who have no caregiver had higher hazards of death as compared with their counterparts. This finding is in line with any other studies [12, 46, 47], Patients with HIV on ART need intensive care and support from their families, relatives, neighbors, and others like health care providers to improve their level of adherence to retain the care. This support may in different perspectives like social, economic(financially), and psychological as well as [12, 42] the existence of this support makes the patient hopeful and can disclose their HIV status to others, this disclosure helps them to collect their medication on time, minimize the level of stigmatization at the workplace and within the community [48]. Therefore the patient belongs to Hope Next and is eager to live more years, for that matter they never interrupt the medication and lost from care, this commitment makes patients less likely to die. Advanced WHO stage III/IV at baseline was an independent predictor of mortality in our study. This finding is consistent with the previous studies [18, 24, 29, 30, 36, 37], the possible reason may be, that the advanced stage of HIV AIDS is due to significant deterioration or depletion of CD4 cell count and ART treatment start at this advanced stage might prone the patients to develop immune reconstitution syndrome(IRIS) [3] which may lead to immediate death. Patients in the advanced clinical stage may develop multiple opportunistic infections and have additional medication for these opportunistic infections (OIs), which makes the patients overburdened with extra medication and become less committed to continuing and interrupting the treatment. Patients in the advanced WHO stage were highly vulnerable to fatal opportunistic infections like Tuberculosis, Cryptococcal meningitis, toxoplasmosis, and intestinal opportunistic infections (OIs) like (cryptosporidium) these Opportunistic Infections (OIs) have independent credit to turn the patients to death [1, 49]. Baseline functional status is an important predictor of mortality among adult PLWH on ART. Those patients with bedridden functional status were at high risk of mortality compared with working functional status [4, 19, 31, 34]. Functional status is strongly associated with an advanced stage of the illness, those patients who were in the advanced stage develop an extra opportunistic infection [8]. These opportunistic infections have been the commonest cause of death in PLWH on ART and those patients bedridden have low immunity status and are unable to cope with the other infections and may be turned to die [1, 2]. The mortality rate among PLWH becomes strongly related to treatment adherence. The hazard of death among HIV-positive patients was higher on the fair and poor level of the last known (recent) adherence level compared with those who have a good level of adherence. This finding is in agreement with other similar studies [21, 24, 25, 28, 29, 31]– [33]. Non-adherence to the care and medication becomes less commitment to the treatment and leads to non-retain in the care, and then the patient interrupts the treatment and may develop treatment failure and opportunistic infection [13].In contrast, patients having good clinical adherence, would not discontinue their treatment, have a consistent follow-up, and are also action-oriented for the counseling from the health care providers, and they might be also psychologically stable to take their treatment properly [48]. The possible Limitations of the study were; Analysis of secondary data faced a problem with incomplete records for important variables like viral load, which is the significant indicator of treatment prognosis as well as an immunologic or virologic marker of the disease’s progress. As mortality is the main target of analysis, then the real cause of death may not be investigated (specified) so all deaths were considered as HIV/AIDS-related, which leads to an overestimation of mortality. Selection bias may have been introduced by the exclusion of patients with missing charts or incomplete variable records for some patients. As a result, if the study’s findings are connected to death, the study participants whose charts were left out or had missing values may have compromised the results. Conclusion Based on our findings the overall survival probability was high among patients on Antiretroviral Therapy (ART) (83.97%) in the seven years of follow-up, and the Mortality rate among HIV-positive patients on ART in the second year of ART initiation is still high in the study population. Baseline clinical WHO stage III/IV, bedridden functional status at enrolment, absence of caregiver, and poor level of recent adherence were found to be independent predictors of mortality within the seven years of follow-up. Hence, giving special attention to patients on WHO stage III/IV and poor level of adherence is crucial to reducing the rate of mortality. As a recommendation; More additional predictors of mortality of patients on ART need to be studied. With future strong study designs like prospective follow-up as well as incorporating qualitative components to capture the patients’ perceptions and attitudes. It is better to conduct competing risk regression analysis to explicit deaths with other causes. This can help to reduce the overestimation of death among RVI-positive patients as well.